ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence

Primary Inclusion Criteria: * Current diagnosis of alcohol dependence, meeting at least 5 of DSM-IV criteria * Expected to complete inpatient treatment for alcohol dependence within 24 hours of randomization * Must have 7-21 days, inclusive, of inpatient treatment for alcohol dependence prior to first dose * Negative urine toxicological screen for opioids on the day of randomization * Women of childbearing potential must agree to use an approved method of contraception for the study duration Primary Exclusion Criteria: * Pregnancy or lactation * Evidence of hepatic failure including: ascites, bilirubin \>10% above upper limit of normal and/or esophageal variceal disease * Current dependence (within the past year) to benzodiazepines, opioids or cocaine by DSM-IV criteria * Use of any opioids and/or methadone within 14 days prior to the screening visit, or subjects likely to require opioid therapy during the study period * Use of oral naltrexone, acamprosate, or disulfiram within 14 days prior to screening * Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or PLG * Parole, probation, or pending legal proceedings having the potential for incarceration during the study period